Liu, Y., Hu, Z., Wang, J., Liao, Y
2021 semaglutide study: remarkable results, side effects, and open questions [30:00]
Ozempic (semaglutide) and Saxenda (liraglutide): vigilance required due to potentially harmful falsified products
in Metabolic and Molecular Bases of Inherited Disease (eds Scriver, C
Heres comprehensive guidance on minimizing risks and ensuring appropriate use
According to the American Diabetes Association guidelines, GLP-1 receptor agonists like semaglutide with proven cardiovascular benefit are recommended for patients with type 2 diabetes who have established atherosclerotic cardiovascular disease and for appropriate candidates requiring weight management